DMPA: Time to repeal black box warning?

October 2011
Contraceptive Technology Update;Oct2011, Vol. 32 Issue 10, p112
Academic Journal
A recently published editorial is calling for the repeal of the black box warning to the labeling for the contraceptive injection, depot medroxyprogesterone acetate (DMPA). The Food and Drug Administration added the warning in 2004 advising that prolonged use might result in bone mineral density loss. The guidance contained in the DMPA black box is not based on evidence, and the warning deprives women of long-term use of a safe and effective contraceptive, the editorial states. The warning cautions users that DMPA should be used as a long-term birth control method (longer than two years) only if other birth control methods are inadequate.


Related Articles

  • FDA advisers uneasy about long-term bisphosphonate use. Traynor, Kate // American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2006 

    The article reports that FDA's panel of experts advised against the long-term use of bisphosphonates for osteoporosis, and suggested that biophosphonate therapy be reevaluated on a periodic basis. It mentions the National Osteoporosis Foundation recommendation on biophosphonate use, and includes...

  • Bone risk low with OTC GERD drugs.  // Clinical Advisor;May2011, Vol. 14 Issue 5, p23 

    The article offers information on the conclusion by the U.S. Food and Drug Administration (FDA) that fracture is unlikely with the short-use use of low-dose proton pump inhibitors (PPI).

  • LEGAL & REGULATORY: Herbal Experts Say CSPI Petition for St. John's Wort Warning Inaccurate. Stafford, Lindsay // HerbalGram;Feb-Apr2012, Issue 93, p58 

    The article reports on a November 2011 decision which the Center for Science in the Public Interest made to urge the U.S. Food and Drug Administration to require detailed warning labels on all St. John's wort products, which are used to treat depression, sleep disorders, anxiety and other...

  • Medication Safety and Reliability. Labels for TNF-alpha blockers to warn of potential for infection.  // Formulary;Oct2011, Vol. 46 Issue 10, p449 

    The article reports on a safety communication which was released by the U.S. Food & Drug Administration on September 7, 2011. In the communication the agency announced that it is requiring the prescribing information for all tumor necrosis factor-alpha blockers to include a black-boxed warning...

  • Osteoporosis: yesterday, today and tomorrow. Lane, Nancy E. // Rheumatology;Jul2011, Vol. 50 Issue 7, p1181 

    The author comments on the changes in the field of osteoporosis treatment. The author relates how the introduction of bisphosphonate etidronate as treatment for osteoporosis energized the field of osteoporosis treatment. Information is presented on the impact of bishosphonate treatment on women...

  • CME Instructions: Calcium score, coronary artery disease extent and severity, and clinical outcomes among low Framingham risk patients with low vs high lifetime risk: Results from the CONFIRM registry.  // Journal of Nuclear Cardiology;Feb2014, Vol. 21 Issue 1, p26 

    No abstract available.

  • Should teens be given depot medroxyprogesterone acetate? Edelman, Alison; Jensen, Jeffrey T. // Contemporary OB/GYN;Apr2006, Vol. 51 Issue 4, p54 

    Examines the prescription of depot medroxyprogesterone acetate (DMPA) as birth control method to teenagers following the black box warning of the U.S. Food and Drug Administration on its adverse effects on bone density. Prevention of the pituitary gland to secrete gonadotropin by the DMPA;...

  • Should adolescent girls be given depot medroxyprogesterone acetate? Edelman, Allison; Jensen, Jeffrey T. // Contemporary Pediatrics;Sep2006, Vol. 23 Issue 9, p105 

    The article examines the health risks if adolescent girls are to be given depot medroxyprogesterone acetate as an effective birth control method in light of a black box warning from the U.S. Food and Drug Administration. The drug includes a progestin-only formulation that can be safely used by...

  • Oral contraceptives effective for long-term treatment. Gagnon, Louise // Dermatology Times;Nov2015 Supplement, Vol. 36, p10 

    The article discusses the use of oral contraceptives (OC) for the treatment of acne. Topics discussed include the risks associated with OCs including venousthromboembolism (VTE) and myocardial infarction (MI) with many being attributable to cigarette smoking in patients who took OCs and the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics